InstalabADMA & SMDA
Should you take a ADMA & SMDA test?
This test is most useful if any of these apply to you.
2 Biomarkers Included
- ADMAThe molecule that directly blocks nitric oxide, the gas that keeps arteries relaxed. It reflects strain on your blood vessel lining and is the more consistent signal of long-term cardiovascular risk.A high result points toward a poorly functioning blood vessel lining and a higher long-term risk of heart attack, stroke, and death.
- SMDASymmetric dimethylarginine, cleared almost entirely by the kidneys, so it rises as filtration declines. It clarifies whether a high reading reflects kidney strain rather than vessel biology.A high result usually signals declining kidney filtration, since the kidneys clear nearly all of this molecule.
About ADMA & SMDA
Your arteries stay open partly because their inner lining releases a gas called nitric oxide that keeps them relaxed. Two naturally occurring molecules in your blood interfere with that system, and measuring them offers a window into strain on your vessels and kidneys that routine labs rarely capture.
This pair is not a standard screening test, and no major medical society yet recommends it for general use. It is used mainly in research and preventive settings to explore early cardiovascular and kidney risk, and the two results are far more informative read side by side than either one alone.
What This Panel Reveals
Both molecules are built from the breakdown of everyday proteins, but they leave the body by different routes, and that difference is the whole point of testing them together. One is a signal about your blood vessels. The other is a signal about your kidneys.
Nitric Oxide and Vessel Strain
Asymmetric dimethylarginine (ADMA) directly blocks the enzyme that makes nitric oxide, so higher levels mean less of the gas that keeps arteries flexible. In human experiments, infusing ADMA raised blood pressure by 6.0%, made blood vessels tighten so they resisted blood flow 23.7% more, and lowered the heart's output by 14.8%, which shows this is an active effect on the circulation rather than a passive bystander.
Because of that biology, ADMA is the marker most consistently tied to hard outcomes. In a pooled analysis of prospective studies, people with the highest ADMA levels had about a 52% higher risk of dying from any cause and a 33% higher risk of cardiovascular disease than those with the lowest. A separate review of 22 studies found a 42% higher risk of cardiovascular disease and a 60% higher risk of stroke comparing the top and bottom thirds.
Kidney Clearance
Symmetric dimethylarginine (the second molecule, labeled SMDA here) has little direct effect on the nitric oxide enzyme. Instead it is cleared almost entirely by your kidneys, so it climbs as filtration declines. Across 18 studies it tracked a gold-standard measure of kidney filtration very closely, with a correlation of 0.85.
That makes the second molecule a sensitive read on kidney function. In people with type 2 diabetes and early kidney involvement, higher levels predicted future cardiovascular events, death, and further decline in filtration, and in one chronic kidney disease group it outperformed ADMA for predicting disease progression.
How to Read Your Results Together
The value of ordering both is that discordant results point to different problems. Reading them as a pair helps separate a vessel signal from a kidney signal.
| Pattern | What It Suggests |
|---|---|
| High ADMA, normal SMDA | Strain is weighted toward the nitric oxide pathway and the vessel lining. Focus attention on cardiovascular risk. |
| Normal ADMA, high SMDA | Strain is weighted toward declining kidney filtration. Confirm with a formal kidney assessment. |
| Both elevated | A combined heart and kidney pattern, generally the higher-risk combination and worth a fuller workup. |
What to Do with Your Results
Neither molecule has a drug that specifically lowers it, and no trial has shown that changing these numbers improves outcomes, so treat them as risk context rather than a target. If ADMA stands out, pair it with an established cardiovascular workup such as particle-based cholesterol and inflammation markers. If the second molecule stands out, confirm kidney function with a cystatin C or an estimated filtration rate before drawing conclusions.
For tracking over time, both molecules are tightly regulated day to day, so a repeat result usually needs to differ by roughly 20% or more before it reflects a real biological change rather than normal fluctuation. Retesting once or twice a year is reasonable if you are actively managing heart or kidney risk, spacing draws far enough apart that a meaningful shift can show.
When Results Can Be Misleading
Kidney function colors the whole panel, especially the second molecule, which can look high simply because filtration is reduced rather than because your vessels are failing. That is exactly why it is read alongside ADMA and your kidney numbers rather than in isolation.
The lab method also matters. Older antibody-based tests and a more precise technique called mass spectrometry can give different readings, so results from different labs are not always interchangeable. Levels also drift up modestly with age. Fasting is not required, since eating changes the values by only about 1%, which is within the test's own margin of error.